{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:38:57Z","timestamp":1790163537192,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:00:00Z","timestamp":1369180800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Targeting signaling pathways is an attractive approach in many malignancies. The PI3K\/Akt\/mTOR pathway is activated in a number of human neoplasms, accompanied by lower overall and\/or disease free survival. mTOR kinase inhibitors have been introduced in the therapy of renal cell carcinoma and mantle cell lymphoma, and several trials are currently underway. However, the pathological characterization of mTOR activity in lymphomas is still incomplete.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>mTOR activity and the elements of mTOR complexes were investigated by immunohistochemistry on tissue microarrays representing different human non-Hodgkin-lymphomas (81 cases) and Hodgkin-lymphomas (87 cases). The expression of phospho-mTOR, phospho-4EBP1, phospho-p70S6K, phospho-S6, Rictor, Raptor and Bcl-2, Bcl-xL, Survivin and NF-kappaB-p50 were evaluated, and mTOR activity was statistically analyzed along with 5-year survival data. The in vitro and in vivo effect of the mTOR inhibitor rapamycin was also examined in human Hodgkin-lymphoma cell lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The majority (&gt;50%) of mantle cell lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, anaplastic large-cell lymphoma and Hodgkin-lymphoma cases showed higher mTOR activity compared to normal lymphoid tissues. Hodgkin-lymphoma was characterized by high mTOR activity in 93% of the cases, and Bcl-xL and NF-kappaB expression correlated with this mTOR activity. High mTOR activity was observed in the case of both favorable and unfavorable clinical response. Low mTOR activity was accompanied by complete remission and at least 5-year disease free survival in Hodgkin-lymphoma patients. However, statistical analysis did not identify correlation beetween mTOR activity and different clinical data of HL patients, such as survival. We also found that Rictor (mTORC2) was not overexpressed in Hodgkin-lymphoma biopsies and cell lines. Rapamycin inhibited proliferation and induced apoptosis in Hodgkin-lymphoma cells both in vitro and in vivo, moreover, it increased the apoptotic effect of chemotherapeutic agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Targeting mTOR activity may be a potential therapeutic tool in lymphomas. The presence of mTOR activity probably indicates that the inclusion of mTOR inhibition in the therapy of Hodgkin-lymphomas may be feasible and beneficial, especially when standard protocols are ineffective, and it may also allow dose reduction in order to decrease late treatment toxicity. Most likely, the combination of mTOR inhibitors with other agents will offer the highest efficiency for achieving the best clinical response.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2407-13-250","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:15:05Z","timestamp":1369181705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease \u2013 a combined tissue microarray, in vitro and in vivo study"],"prefix":"10.1186","volume":"13","author":[{"given":"\u00c1gnes","family":"M\u00e1rk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Hajdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"V\u00e1radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s B\u00e9la","family":"Sticz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Csomor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Berczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Cs\u00f3ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Kopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sebesty\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,22]]},"reference":[{"key":"3885_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3324\/haematol.2010.034264","volume":"96","author":"R Marcos-Gragera","year":"2011","unstructured":"Marcos-Gragera R, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Maynadie M, Luminari S, Ferretti S, Johannesen TB, Sankila R, Karjalainen-Lindsberg ML, Simonetti A, Martos MC, Rapha\u00ebl M, Giraldo P, Sant M, HAEMACARE Working Group: Survival of European patients diagnosed with lymphoid neoplasms in 2000\u20132002: results of the HAEMACARE project. Haematologica. 2011, 96: 720-8. 10.3324\/haematol.2010.034264.","journal-title":"Haematologica"},{"key":"3885_CR2","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","volume":"29","author":"C Steidl","year":"2011","unstructured":"Steidl C, Connors JM, Gascoyne RD: Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment. JCO. 2011, 29: 1812-1826. 10.1200\/JCO.2010.32.8401.","journal-title":"JCO"},{"key":"3885_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1470-2045(03)01319-6","volume":"5","author":"RK Thomas","year":"2004","unstructured":"Thomas RK, Re D, Wolf J, Diehl V: Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004, 5: 11-8. 10.1016\/S1470-2045(03)01319-6.","journal-title":"Lancet Oncol"},{"key":"3885_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.biocel.2003.10.025","volume":"37","author":"R K\u00fcppers","year":"2005","unstructured":"K\u00fcppers R, Hansmann ML: The Hodgkin and Reed\/Sternberg cell. Int J Biochem Cell Biol. 2005, 37: 511-7. 10.1016\/j.biocel.2003.10.025.","journal-title":"Int J Biochem Cell Biol"},{"key":"3885_CR5","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/cncr.24178","volume":"115","author":"O Favier","year":"2009","unstructured":"Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van't Veer MB, Aleman BM, Noordijk EM, Thomas J, Ferm\u00e9 C, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA): Survival after Hodgkin lymphoma. Cancer. 2009, 115: 1680-91. 10.1002\/cncr.24178.","journal-title":"Cancer"},{"key":"3885_CR6","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1182\/blood-2004-12-4750","volume":"105","author":"D Re","year":"2005","unstructured":"Re D, Thomas RK, Behringer K, Diehl V: From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 2005, 105: 4553-60. 10.1182\/blood-2004-12-4750.","journal-title":"Blood"},{"key":"3885_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5045\/kjh.2012.47.1.8","volume":"47","author":"ES Currin","year":"2012","unstructured":"Currin ES, Gopal AK: Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. Korean J Hematol. 2012, 47: 8-16. 10.5045\/kjh.2012.47.1.8.","journal-title":"Korean J Hematol"},{"key":"3885_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrclinonc.2010.84","volume":"7","author":"C Fert\u00e9","year":"2010","unstructured":"Fert\u00e9 C, Andr\u00e9 F, Soria JC: Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol. 2010, 7: 367-80. 10.1038\/nrclinonc.2010.84.","journal-title":"Nat Rev Clin Oncol"},{"key":"3885_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM: mTOR Signaling in Growth Control and Disease. Cell. 2012, 149: 274-93. 10.1016\/j.cell.2012.03.017.","journal-title":"Cell"},{"key":"3885_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 2007, 12: 9-22. 10.1016\/j.ccr.2007.05.008.","journal-title":"Cancer Cell"},{"key":"3885_CR11","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H P\u00f3pulo","year":"2012","unstructured":"P\u00f3pulo H, Lopes JM, Soares P: The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci. 2012, 13: 1886-918. 10.3390\/ijms13021886.","journal-title":"Int J Mol Sci"},{"key":"3885_CR12","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-10-0480","volume":"16","author":"C Vu","year":"2010","unstructured":"Vu C, Fruman DA: Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res. 2010, 16: 5374-80. 10.1158\/1078-0432.CCR-10-0480.","journal-title":"Clin Cancer Res"},{"key":"3885_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","volume":"4","author":"N Chalhoub","year":"2009","unstructured":"Chalhoub N, Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009, 4: 127-50. 10.1146\/annurev.pathol.4.110807.092311.","journal-title":"Annu Rev Pathol"},{"key":"3885_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11523-011-0175-8","volume":"6","author":"KR Kelly","year":"2011","unstructured":"Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS: Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011, 6: 53-61. 10.1007\/s11523-011-0175-8.","journal-title":"Target Oncol"},{"key":"3885_CR15","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/leu.2010.170","volume":"24","author":"N Chapuis","year":"2010","unstructured":"Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D: Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia. 2010, 24: 1686-99. 10.1038\/leu.2010.170.","journal-title":"Leukemia"},{"key":"3885_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrc1974","volume":"6","author":"DM Sabatini","year":"2006","unstructured":"Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006, 6: 729-34. 10.1038\/nrc1974.","journal-title":"Nat Rev Cancer"},{"key":"3885_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-011-0178-5","volume":"6","author":"Y Alvarado","year":"2011","unstructured":"Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D: Clinical activity of mTORIs in solid tumors. Targ Oncol. 2011, 6: 69-94. 10.1007\/s11523-011-0178-5.","journal-title":"Targ Oncol"},{"key":"3885_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11912-011-0187-7","volume":"13","author":"JH Schatz","year":"2011","unstructured":"Schatz JH: Targeting the PI3K\/AKT\/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011, 13: 398-406. 10.1007\/s11912-011-0187-7.","journal-title":"Curr Oncol Rep"},{"key":"3885_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1615\/CritRevOncog.v17.i1.60","volume":"17","author":"K Sheppard","year":"2012","unstructured":"Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA: Targeting PI3 kinase\/AKT\/mTOR signaling in cancer. Crit Rev Oncog. 2012, 17: 69-95. 10.1615\/CritRevOncog.v17.i1.60.","journal-title":"Crit Rev Oncog"},{"key":"3885_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/BF02893956","volume":"2","author":"R Mihalik","year":"1996","unstructured":"Mihalik R, Uher F, Pocsik \u00c9E, Berczi L, Benczur M, Kopper L: Detection of Drug-induced Apoptosis by Flow Cytometry after Alkaline Extraction of Ethanol Fixed Cells. Pathol Oncol Res. 1996, 2: 78-83. 10.1007\/BF02893956.","journal-title":"Pathol Oncol Res"},{"key":"3885_CR21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/modpathol.2012.141","volume":"25","author":"A Sebesty\u00e9n","year":"2012","unstructured":"Sebesty\u00e9n A, Sticz TB, M\u00e1rk \u00c1, Hajdu M, Tim\u00e1r B, Nemes K, Nagy N, V\u00e1radi Z, Kopper L: Activity and complexes of mTOR in diffuse large B-cell lymphomas \u2013 a tissue microarray study. Mod Pathol. 2012, 25: 1623-8. 10.1038\/modpathol.2012.141.","journal-title":"Mod Pathol"},{"key":"3885_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.blre.2010.08.003","volume":"24","author":"A Jona","year":"2010","unstructured":"Jona A, Younes A: Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010, 24: 233-8. 10.1016\/j.blre.2010.08.003.","journal-title":"Blood Rev"},{"key":"3885_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","volume":"5","author":"V Diehl","year":"2004","unstructured":"Diehl V, Thomas RK, Re D: Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol. 2004, 5: 19-26. 10.1016\/S1470-2045(03)01320-2.","journal-title":"Lancet Oncol"},{"key":"3885_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","volume":"205","author":"A Dutton","year":"2005","unstructured":"Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005, 205: 498-506. 10.1002\/path.1725.","journal-title":"J Pathol"},{"key":"3885_CR25","first-page":"55","volume":"3","author":"J De","year":"2010","unstructured":"De J, Brown RE: Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma. Int J Clin Exp Med. 2010, 3: 55-68.","journal-title":"Int J Clin Exp Med"},{"key":"3885_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005, 16: 525-37. 10.1093\/annonc\/mdi113.","journal-title":"Ann Oncol"},{"key":"3885_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/blood-2002-04-1128","volume":"101","author":"JF Garc\u00eda","year":"2003","unstructured":"Garc\u00eda JF, Camacho FI, Morente M, Fraga M, Montalb\u00e1n C, Alvaro T, Bellas C, Casta\u00f1o A, D\u00edez A, Flores T, Martin C, Martinez MA, Mazorra F, Men\u00e1rguez J, Mestre MJ, Mollejo M, S\u00e1ez AI, S\u00e1nchez L, Piris MA, Spanish Hodgkin Lymphoma Study Group: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003, 101: 681-9. 10.1182\/blood-2002-04-1128.","journal-title":"Blood"},{"key":"3885_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2141.2009.07889.x","volume":"147","author":"MA Pulsipher","year":"2009","unstructured":"Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N: A phase I\/II study of the safety and efficacy of the addition of sirolimus to tacrolimus\/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol. 2009, 147: 691-9. 10.1111\/j.1365-2141.2009.07889.x.","journal-title":"Br J Haematol"},{"key":"3885_CR29","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1093\/annonc\/mds057","volume":"23","author":"E Seront","year":"2012","unstructured":"Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP: Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012, 23: 2663-70. 10.1093\/annonc\/mds057.","journal-title":"Ann Oncol"},{"key":"3885_CR30","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/annonc\/mds075","volume":"23","author":"C Villarreal-Garza","year":"2012","unstructured":"Villarreal-Garza C, Cortes J, Andre F, Verma S: mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol. 2012, 23: 2526-35. 10.1093\/annonc\/mds075.","journal-title":"Ann Oncol"},{"key":"3885_CR31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jtcvs.2012.06.049","volume":"144","author":"SH Li","year":"2012","unstructured":"Li SH, Huang EY, Lu HI, Huang WT, Yen CC, Huang WC, Chen CH: Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2012, 144: 1352-9. 10.1016\/j.jtcvs.2012.06.049.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3885_CR32","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2004-11-4513","volume":"106","author":"F Jundt","year":"2005","unstructured":"Jundt F, Raetzel N, M\u00fcller C, Calkhoven CF, Kley K, Mathas S, Lietz A, Leutz A, D\u00f6rken B: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005, 106: 1801-7. 10.1182\/blood-2004-11-4513.","journal-title":"Blood"},{"key":"3885_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drup.2008.03.001","volume":"11","author":"BH Jiang","year":"2008","unstructured":"Jiang BH, Liu LZ: Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat. 2008, 11: 63-76. 10.1016\/j.drup.2008.03.001.","journal-title":"Drug Resist Updat"},{"key":"3885_CR34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE: A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010, 85: 320-4.","journal-title":"Am J Hematol"},{"key":"3885_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/j.1875-9114.2012.01084.x","volume":"32","author":"CM Barnett","year":"2012","unstructured":"Barnett CM: Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy. 2012, 32: 383-96. 10.1002\/j.1875-9114.2012.01084.x.","journal-title":"Pharmacotherapy"},{"key":"3885_CR36","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.4161\/cc.10.14.16586","volume":"10","author":"WJ Oh","year":"2011","unstructured":"Oh WJ, Jacinto E: mTOR complex 2 signaling and functions. Cell Cycle. 2011, 10: 2305-16. 10.4161\/cc.10.14.16586.","journal-title":"Cell Cycle"},{"key":"3885_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bbrc.2007.07.151","volume":"362","author":"A Akcakanat","year":"2007","unstructured":"Akcakanat A, Singh G, Hung MC, Meric-Bernstam F: Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun. 2007, 362: 330-3. 10.1016\/j.bbrc.2007.07.151.","journal-title":"Biochem Biophys Res Commun"},{"key":"3885_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell. 2006, 22: 159-68. 10.1016\/j.molcel.2006.03.029.","journal-title":"Mol Cell"},{"key":"3885_CR39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/CCO.0b013e32834b892d","volume":"23","author":"NZ Khokhar","year":"2011","unstructured":"Khokhar NZ, Altman JK, Platanias LC: Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol. 2011, 23: 578-86. 10.1097\/CCO.0b013e32834b892d.","journal-title":"Curr Opin Oncol"},{"key":"3885_CR40","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1158\/1078-0432.CCR-05-0422","volume":"11","author":"FA Baker","year":"2005","unstructured":"Baker FA, Tomislav D, Nathan TI, Williams R, Fenoglio-Preiser C, Powie G: Stability of Phosphoprotein as a Biological Marker of Tumor Signaling. Clin Cancer Res. 2005, 11: 4338-4340. 10.1158\/1078-0432.CCR-05-0422.","journal-title":"Clin Cancer Res"},{"key":"3885_CR41","doi-asserted-by":"publisher","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-07-2223","volume":"67","author":"J Masri","year":"2007","unstructured":"Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J: mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007, 67: 11712-20. 10.1158\/0008-5472.CAN-07-2223.","journal-title":"Cancer Res"},{"key":"3885_CR42","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1158\/1078-0432.CCR-09-1249","volume":"15","author":"P Gulhati","year":"2009","unstructured":"Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T, Evers BM: Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res. 2009, 15: 7207-16. 10.1158\/1078-0432.CCR-09-1249.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-250\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T23:31:20Z","timestamp":1715383880000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3885"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-250","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,22]]},"assertion":[{"value":"11 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"250"}}